Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 6, 2015

View Archived Issues

Isomerase Therapeutics discloses novel polyketide FKBP1A inhibitors

New preclinical data on JNK inhibitors for the treatment of neurological diseases

First evidence for SESN3 gene as a modulator of proconvulsant gene network

Ligand signs license agreement with Sermonix for lasofoxifene

Trevena presents an innovative composite endpoint for BLAST-AHF trial

WaVe Life Sciences closes Series A financing

Moderna Therapeutics and Institut Pasteur form infectious disease research collaboration

Allegro's phase II study of Luminate for DME supported by grant

Genmab reports data from phase II study of daratumumab in refractory multiple myeloma

Mast Therapeutics begins phase IIa studies of AIR-001 in heart failure

Ironwood Pharmaceuticals reports data from exploratory phase IIa trial of IW-3718 in GERD

Proteostasis Therapeutics selects PTI-130 as a development candidate for CF

OncoMed begins dosing in phase II study of demcizumab in NSCLC

Motif Bio seeks to raise funds to support pipeline

Lundbeck reviews fourth quarter 2014

BrainStorm reports positive recommendation in ongoing phase II trial of NurOwn

Ayoxxa and SERI collaborate on protein multiplexing technology platform for ophthalmology

FDA clears Sangamo to begin phase I/II study of its ZFP Therapeutic for beta-thalassemia

Albireo initiates phase II trial of A-4250 in patients with primary biliary cirrhosis

Mylan to acquire female reproductive health care businesses from Famy Care

Bayer Schering Pharma reports dual sGC activators/PDE5 inhibitors

The Medicines Company completes acquisition of Annovation Biopharma

Dehydroleucodine derivatives patented by U.S. and Ecuador Universities

Gilead presents new anti-HIV compounds

Takeda discloses new MCHR-1 antagonists

Revolution Medicines launched to discover optimized analogues of natural products

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.